Skip to content

Nuvalent, Inc. NUVL Additional Paid-In Capital

Additional Paid-In Capital at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Incyte logo
IncyteINCY
ALN
Alnylam PharmaceuticalsALNY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s additional paid-in capital?
Nuvalent, Inc. (NUVL) reported additional paid-in capital of $2.26B in Q1 2026.
How has Nuvalent, Inc.'s additional paid-in capital changed year-over-year?
Nuvalent, Inc.'s additional paid-in capital increased by 37.5% year-over-year, from $1.64B to $2.26B.
What is the long-term trend for Nuvalent, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s additional paid-in capital has grown at a 383.2% compound annual growth rate (CAGR), from $842K to $2.22B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.